Literature DB >> 21505567

Differential Inductive Signaling of CD90 Prostate Cancer-Associated Fibroblasts Compared to Normal Tissue Stromal Mesenchyme Cells.

Laura E Pascal, Junkui Ai, Ricardo Z N Vêncio, Eneida F Vêncio, Yong Zhou, Laura S Page, Lawrence D True, Zhou Wang, Alvin Y Liu.   

Abstract

UNLABELLED: Prostate carcinomas are surrounded by a layer of stromal fibroblastic cells that are characterized by increased expression of CD90. These CD90(+) cancer-associated stromal fibroblastic cells differ in gene expression from their normal counterpart, CD49a(+)CD90(lo) stromal smooth muscle cells; and were postulated to represent a less differentiated cell type with altered inductive properties. CD90(+) stromal cells were isolated from tumor tissue specimens and co-cultured with the pluripotent embryonal carcinoma cell line NCCIT in order to elucidate the impact of tumor-associated stroma on stem cells, and the 'cancer stem cell.' Transcriptome analysis identified a notable decreased induction of smooth muscle and prostate stromal genes such as PENK, BMP2 and ChGn compared to previously determined NCCIT response to normal prostate stromal cell induction. CD90(+) stromal cell secreted factors induced an increased expression of CD90 and differential induction of genes involved in extracellular matrix remodeling and the RECK pathway in NCCIT. These results suggest that, compared to normal tissue stromal cells, signaling from cancer-associated stromal cells has a markedly different effect on stem cells as represented by NCCIT. Given that stromal cells are important in directing organ-specific differentiation, stromal cells in tumors appear to be defective in this function, which may contribute to abnormal differentiation found in diseases such as cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12307-010-0061-4) contains supplementary material, which is available to authorized users.

Entities:  

Keywords:  Cancer stem cell; Prostate; Prostate cancer; Reversion-inducing cysteine-rich protein with Kazal motifs (RECK); Tumor-associated stroma

Year:  2011        PMID: 21505567      PMCID: PMC3047627          DOI: 10.1007/s12307-010-0061-4

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  27 in total

1.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

Authors:  Rafael A Irizarry; Bridget Hobbs; Francois Collin; Yasmin D Beazer-Barclay; Kristen J Antonellis; Uwe Scherf; Terence P Speed
Journal:  Biostatistics       Date:  2003-04       Impact factor: 5.899

2.  Mass spectrometric detection of tissue proteins in plasma.

Authors:  Hui Zhang; Alvin Y Liu; Paul Loriaux; Bernd Wollscheid; Yong Zhou; Julian D Watts; Ruedi Aebersold
Journal:  Mol Cell Proteomics       Date:  2006-10-09       Impact factor: 5.911

3.  Analysis of prostate cancer by proteomics using tissue specimens.

Authors:  Alvin Y Liu; Hui Zhang; Carrie M Sorensen; Deborah L Diamond
Journal:  J Urol       Date:  2005-01       Impact factor: 7.450

4.  Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling.

Authors:  Jennifer A Tuxhorn; Gustavo E Ayala; Megan J Smith; Vincent C Smith; Truong D Dang; David R Rowley
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

5.  Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT.

Authors:  I Damjanov; B Horvat; Z Gibas
Journal:  Lab Invest       Date:  1993-02       Impact factor: 5.662

Review 6.  RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer.

Authors:  Jonathan C M Clark; David M Thomas; Peter F M Choong; Crispin R Dass
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

7.  Temporal expression profiling of the effects of secreted factors from prostate stromal cells on embryonal carcinoma stem cells.

Authors:  Laura E Pascal; Ricardo Z N Vêncio; Young Ah Goo; Laura S Page; Christina P Shadle; Alvin Y Liu
Journal:  Prostate       Date:  2009-09-01       Impact factor: 4.104

8.  Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue.

Authors:  Thomas Ernst; Manfred Hergenhahn; Marc Kenzelmann; Clemens D Cohen; Mahnaz Bonrouhi; Annette Weninger; Ralf Klären; Elisabeth F Gröne; Manfred Wiesel; Christof Güdemann; Jens Küster; Winfried Schott; Gerd Staehler; Matthias Kretzler; Monica Hollstein; Hermann-Josef Gröne
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

9.  Global expression analysis of prostate cancer-associated stroma and epithelia.

Authors:  Annely M Richardson; Karen Woodson; Yonghong Wang; Jaime Rodriguez-Canales; Heidi S Erickson; Michael A Tangrea; Kristian Novakovic; Sergio Gonzalez; Alfredo Velasco; Ernest S Kawasaki; Michael R Emmert-Buck; Rodrigo F Chuaqui; Audrey Player
Journal:  Diagn Mol Pathol       Date:  2007-12

10.  Molecular and cellular characterization of ABCG2 in the prostate.

Authors:  Laura E Pascal; Asa J Oudes; Timothy W Petersen; Young Ah Goo; Laura S Walashek; Lawrence D True; Alvin Y Liu
Journal:  BMC Urol       Date:  2007-04-10       Impact factor: 2.264

View more
  10 in total

1.  PDGF-D promotes dermal fibroblast invasion in 3-dimensional extracellular matrix via Snail-mediated MT1-MMP upregulation.

Authors:  Zhuo Qin; Jinfa Feng; Yusi Liu; Li-Li Deng; Changlian Lu
Journal:  Tumour Biol       Date:  2015-08-04

2.  Bladder expression of CD cell surface antigens and cell-type-specific transcriptomes.

Authors:  Alvin Y Liu; Ricardo Z N Vêncio; Laura S Page; Melissa E Ho; Michelle A Loprieno; Lawrence D True
Journal:  Cell Tissue Res       Date:  2012-03-20       Impact factor: 5.249

Review 3.  Reprogramming of prostate cancer cells--technical challenges.

Authors:  Gisely T Borges; Eneida F Vêncio; Ricardo Z N Vêncio; Robert L Vessella; Carol B Ware; Alvin Y Liu
Journal:  Curr Urol Rep       Date:  2015-01       Impact factor: 3.092

Review 4.  Multiple roles of CD90 in cancer.

Authors:  Atul Kumar; Anshuman Bhanja; Jina Bhattacharyya; Bithiah Grace Jaganathan
Journal:  Tumour Biol       Date:  2016-06-23

Review 5.  Isolation and analysis of discreet human prostate cellular populations.

Authors:  Douglas W Strand; LaTayia Aaron; Gervaise Henry; Omar E Franco; Simon W Hayward
Journal:  Differentiation       Date:  2015-11-03       Impact factor: 3.880

6.  Selection and Evaluation of Specific Single Chain Antibodies against CD90, a Marker for Mesenchymal and Cancer Stem Cells.

Authors:  Bahareh Moazen; Amir Zarrinhaghighi; Foroogh Nejatollahi
Journal:  Rep Biochem Mol Biol       Date:  2018-10

7.  Lineage relationship of prostate cancer cell types based on gene expression.

Authors:  Laura E Pascal; Ricardo Zn Vêncio; Robert L Vessella; Carol B Ware; Eneida F Vêncio; Gareth Denyer; Alvin Y Liu
Journal:  BMC Med Genomics       Date:  2011-05-23       Impact factor: 3.063

8.  The opposing action of stromal cell proenkephalin and stem cell transcription factors in prostate cancer differentiation.

Authors:  Alvin Y Liu
Journal:  BMC Cancer       Date:  2021-12-15       Impact factor: 4.430

9.  Development of a reactive stroma associated with prostatic intraepithelial neoplasia in EAF2 deficient mice.

Authors:  Laura E Pascal; Junkui Ai; Khalid Z Masoodi; Yujuan Wang; Dan Wang; Kurtis Eisermann; Lora H Rigatti; Katherine J O'Malley; Hei M Ma; Xinhui Wang; Javid A Dar; Anil V Parwani; Brian W Simons; Michael M Ittman; Luyuan Li; Benjamin J Davies; Zhou Wang
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

10.  A reduction in CD90 (THY-1) expression results in increased differentiation of mesenchymal stromal cells.

Authors:  Daniela A Moraes; Tatiana T Sibov; Lorena F Pavon; Paula Q Alvim; Raphael S Bonadio; Jaqueline R Da Silva; Aline Pic-Taylor; Orlando A Toledo; Luciana C Marti; Ricardo B Azevedo; Daniela M Oliveira
Journal:  Stem Cell Res Ther       Date:  2016-07-28       Impact factor: 6.832

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.